Keyword: Vasant Narasimhan
Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.
Without Alcon, Novartis will be able to better focus on high-margin biopharma development, says CEO Vas Narasimhan.
Switzerland's attorney general found no grounds for bribery charges related to Novartis' $1.2 million in payments to Trump attorney Michael Cohen.
Former Novartis CEO Joe Jimenez was set to join the board of a leading hedge fund, but the plans are now on hold, WSJ reports.
Two people signed Novartis' contract with Michael Cohen, and now they've both left: Ex-CEO Joe Jimenez and GC Felix Ehrat, who stepped down Wednesday.
Swiss law enforcement officials are weighing their own investigation into Basel-based Novartis and its questionable payments to President Trump's personal lawyer.
If Novartis thought public statements this week would silence questions about its $1.2 million contract with Michael Cohen, it was wrong.
Novartis CEO Vas Narasimhan acknowledged the company “made a mistake” by striking a $1.2 million deal with Trump lawyer Michael Cohen.
After round-the-world scandals, it certainly appears Novartis has a systemic problem. But Vas Narasimhan has a clean slate—and he needs to use it.
Novartis' account of the Michael Cohen deal leaves plenty of unanswered questions.